Thymosin β4 Oligodendrocyte Differentiation for Axonal Myelination

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments are inadequate for promoting functional recovery after stroke and multiple sclerosis, as well as neural injury and neurodegenerative diseases, with no established effective methods for inducing axonal plasticity and oligodendrogenesis.

Innovation Solution

Administration of thymosin β4 to promote the proliferation, migration, and differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes, which myelinate damaged axons, thereby improving neurological function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for stroke and multiple sclerosis, then basic medical care is provided, but functional neurological recovery is incomplete and axonal plasticity is not induced

Engineering Contradiction:

Improvefunctional neurological recoveryVSAvoidaxonal plasticity induction

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by administering thymosin β4 at specific dosages (e.g., 1-10 mg/kg body weight) and timing (within 24-48 hours of injury onset) to transform the biological state of oligodendrocyte progenitor cells, inducing their differentiation into mature oligodendrocytes and promoting axonal plasticity that conventional treatments fail to achieve

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

Thymosin β4 serves as an intermediary substance that mediates between the injury site and oligodendrocyte progenitor cells, facilitating their migration, proliferation, and differentiation to produce myelin and promote axonal recovery, thereby bridging the gap between injury and functional restoration

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If early treatment is administered, then neurological outcome is improved, but treatment window is limited

Engineering Contradiction:

Improveneurological outcomeVSAvoidtreatment window

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent implements preliminary action by administering thymosin β4 within a critical early window (24-48 hours post-injury) to preemptively stimulate oligodendrocyte progenitor cell differentiation and myelin production before secondary damage occurs, thereby improving neurological outcomes while extending the effective treatment window beyond conventional approaches

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS9149509B2Methods for improving neurological outcome after neural injury and neurodegenerative disease

Publication Date: 2015.10.06 HENRY FORD HEALTH SYST

AI summary

Thymosin β4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by neurological and neurodegenerative disease. In particular, stroke and multiple sclerosis are examples of conditions which may be ameliorated by treatment with thymosin β4. Thymosin β4 has been found to restore neurological tissue through several effects on several neurological parameters which are improved by administration of thymosin β4 to a subject in need of neurological tissue restoration. For example, thymosin β4 improves axonal myelination, migration of neural progenitor cells, neural progenitor cell proliferation, differentiation of neural progenitor cells into mature neurons, differentiation of neural progenitor cells into mature glia, nerve regeneration, and brain remodeling at locations of brain injury.